selective serotonin reuptake inhibitor

New research suggests that selective serotonin reuptake inhibitor (SSRI) antidepressants may help people move again after a stroke.

We recently discussed the severe challenges to evidence-based medicine presented by manipulation and suppression of clinical research to serve vested interests.  I recently (and unfortunately belatedly) came upon yet another example of suppression of research that was unfavorable to a research sponsor's vested inter

On the Clinical Psychology and Psychiatry Blog, the anonymous blogger described an interesting example of apparent dual publication on a selective serotonin reuptake inhibitor (SSRI) anti-depressant drug, duloxetine (Cymbalta, manufactured by Eli Lilly).

Concerns about manipulation and suppression of the clinical research literature are gaining more traction. Recently, Alison Bass published Side Effects, a book that explored one of the more vivid cases.

As described by a reviewer in the New England Journal of Medicine,(1)

She has used the case of Paxil to expose the unsavory and self-serving relationships among members of the pharmaceutical industry, psychiatrists, and members of the FDA.

The reviewer concluded,

I found this a little belatedly, but then again, it is from a slightly obscure source (at least, if one lives on the East Coast of the US).